Why do you think a partner/buyout candidate should or will come from the "small or 'Boutique' bio-med arena" ?
Wouldn't a BP, that is cash-heavy, be more favorable? Some time ago I pointed to Eli Lilly that try to push their Alzheimer development forward and that are interested especially in the field of tau or combined Amyloid/tau therapeutics where ILNS has a lot of patents and patent application to secure the IP.
And there are of course others that could very well use the IP and developments of ILNS.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.